©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Multidrug Resistance Protein (MRP)-mediated Transport of Leukotriene C and Chemotherapeutic Agents in Membrane Vesicles
DEMONSTRATION OF GLUTATHIONE-DEPENDENT VINCRISTINE TRANSPORT (*)

(Received for publication, November 30, 1995; and in revised form, January 17, 1996)

Douglas W. Loe (1) Kurt C. Almquist (1) (2)(§) Roger G. Deeley (1) (2)(¶) Susan P. C. Cole (1) (2)(**)

From the  (1)Cancer Research Laboratories and (2)Department of Pathology, Queen's University, Kingston, Ontario, K7L 3N6 Canada

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

The 190-kDa multidrug resistance protein (MRP) has recently been associated with the transport of cysteinyl leukotrienes and several glutathione (GSH) S-conjugates. In the present study, we have examined the transport of leukotriene C(4) (LTC(4)) in membrane vesicles from MRP-transfected HeLa cells (T14), as well as drug-selected H69AR lung cancer cells which express high levels of MRP. V(max) and K values for LTC(4) transport by membrane vesicles from T14 cells were 529 ± 176 pmol mg min and 105 ± 31 nM, respectively. At 50 nM LTC(4), the K (ATP) was 70 µM. Transport in T14 vesicles was osmotically-sensitive and was supported by various nucleoside triphosphates but not by non- or slowly-hydrolyzable ATP analogs. LTC(4) transport rates in membrane vesicles derived from H69AR cells and their parental and revertant variants were consistent with their relative levels of MRP expression. A 190-kDa protein in T14 membrane vesicles was photolabeled by [^3H]LTC(4) and immunoprecipitation with MRP-specific monoclonal antibodies (mAbs) confirmed that this protein was MRP. LTC(4) transport was inhibited by an MRP-specific mAb (QCRL-3) directed against an intracellular conformational epitope of MRP, but not by a mAb (QCRL-1) which recognizes a linear epitope. Photolabeling with [^3H]LTC(4) was also inhibitable by mAb QCRL-3 but not mAb QCRL-1. GSH did not inhibit LTC(4) transport. However, the ability of alkylated GSH derivatives to inhibit transport increased markedly with the length of the alkyl group. S-Decylglutathione was a potent competitive inhibitor of [^3H]LTC(4) transport (K 116 nM), suggesting that the two compounds bind to the same, or closely related, site(s) on MRP. Chemotherapeutic agents including colchicine, doxorubicin, and daunorubicin were poor inhibitors of [^3H]LTC(4) transport. Taxol, VP-16, vincristine, and vinblastine were also poor inhibitors of LTC(4) transport but inhibition by these compounds was enhanced by GSH. Uptake of [^3H]vincristine into T14 membrane vesicles in the absence of GSH was low and not dependent on ATP. However, in the presence of GSH, ATP-dependent vincristine transport was observed. Levels of transport increased with concentrations of GSH up to 5 mM. The identification of an MRP-specific mAb that inhibits LTC(4) transport and prevents photolabeling of MRP by LTC(4), provides conclusive evidence of the ability of MRP to transport cysteinyl leukotrienes. Our studies also demonstrate that MRP is capable of mediating ATP-dependent transport of vincristine and that transport is GSH-dependent.


INTRODUCTION

Multidrug resistance can be conferred by overexpression of either the multidrug resistance protein, MRP(^1)(1) , or by P-glycoprotein(2) . Both MRP and P-glycoprotein belong to the ATP-binding cassette transporter superfamily but share only approximately 15% amino acid identity(3) . Considerable evidence suggests that P-glycoprotein reduces cellular drug accumulation by acting as an ATP-dependent drug efflux pump(2, 4) , but the mechanism of action of MRP is much less certain. The ability to transport drugs directly into plasma membrane vesicles has been firmly established for P-glycoprotein(5, 6) , but not for MRP. There is also no evidence that xenobiotics bind directly to MRP(7, 8) , as has been demonstrated for P-glycoprotein by cross-linking studies with photoaffinity analogs of chemotherapeutic agents(9) . These observations suggest that these two ATP-binding cassette proteins may confer multidrug resistance by different mechanisms.

Some insight into the normal physiological role of MRP has been obtained by the demonstration that membrane vesicles from MRP-overexpressing drug-selected and transfected cells support ATP-dependent transport of cysteinyl leukotrienes (e.g. LTC(4)) and certain other GSH S-conjugates(10, 11, 12) . Further evidence of a role for MRP in LTC(4) transport was suggested by the observation that photolabeling of a 190-kDa protein with LTC(4) in MRP-expressing cells is inhibited by MK571 (an inhibitor of LTC(4) transport)(10) . The cysteinyl leukotrienes are potent mediators of inflammation that increase vascular permeability and smooth muscle contraction(13) . LTC(4) is synthesized from GSH and LTA(4) by LTC(4) synthase(14) . It is then exported from the cell by an ATP-dependent transport mechanism(15) . LTC(4) synthase and the LTC(4) transporter protein are expressed in eosinophils and mast cells(16) , as well as endothelial cells(13) . LTC(4) is also transported in the liver by at least two routes: uptake from the blood circulation into hepatocytes, and excretion from hepatocytes across canalicular membranes into the bile(13) .

Although current evidence strongly suggests that MRP mediates an active transport process, the mechanistic relationship between the involvement of MRP in GSH S-conjugate transport and its role in multidrug resistance is unclear. GSH conjugation is not known to be an important pathway for the biotransformation of chemotherapeutic agents to which MRP confers resistance and there is no evidence that this reaction occurs to any significant extent in tumor cells or drug-resistant tumor cell lines(17) .

In the present study, the mechanism by which MRP confers resistance to multiple drugs was investigated in a plasma membrane vesicle model system. For these studies, we used membrane vesicles from a population of HeLa cells, termed T14, which had been transfected with a MRP expression vector(8) . By using transfected cells as the source of membrane vesicles, those aspects of LTC(4) and drug transport kinetics that are solely attributable to MRP overexpression can be identified(8, 18) . Our initial objective was to characterize MRP-mediated LTC(4) transport in membrane vesicles from this new population of transfected HeLa cells so that subsequent studies of drug, or drug conjugate, transport could be evaluated within this context. We provide evidence that [^3H]LTC(4) binds specifically to MRP and demonstrate that a MRP-specific mAb inhibits both [^3H]LTC(4) transport and binding. We have also characterized the ability of alkylated GSH derivatives and hydrophobic chemotherapeutic agents to inhibit [^3H]LTC(4) transport. Finally, we show that GSH not only enhances the ability of vincristine to inhibit LTC(4) transport, but also results in ATP-dependent transport of the drug itself.


EXPERIMENTAL PROCEDURES

Materials

[14,15,19,20-^3H]-LTC(4) (128 Ci mmol) and [S]methionine (710 Ci mmol) were purchased from DuPont NEN (Mississauga, Ontario, Canada), and [^3H]vincristine (VCR) (6.9 Ci mmol) was from Amersham (Oakville, Ontario, Canada). LTB(4), LTC(4), VP-16, AMP, AMP-PNP, AMP-PCP, ATPS, GTP, CTP, UTP, colchicine, GSH, GSSG, and S-alkyl GSH derivatives were from Sigma. ATP, daunorubicin, doxorubicin, vinblastine, and VCR were purchased from ICN Biochemicals (St. Laurent, PQ, Canada) and taxol was from Omicron BioChemicals (San Antonio, TX). Creatine phosphate and creatine kinase were from Boehringer Mannheim (Dorval, PQ, Canada). QCRL-3 is a IgG murine mAb that recognizes a conformation dependent epitope of MRP and has been described previously(19) .

Cell Culture

The small cell lung cancer cell line H69, its doxorubicin-selected multidrug resistant H69AR, and the drug-sensitive revertant cell line, H69PR, have been described previously(3, 20) . The HeLa cells transfected with the pCEBV7 vector (C6) or the vector containing the MRP coding sequence pCEBV7-MRP1 (T14) have also been described(8) . The 8226/Dox40 cell line overexpresses P-glycoprotein (21) and was provided by Dr. W. Dalton. All cell lines were cultured in RPMI 1640 medium with 5% defined bovine calf serum (HyClone Laboratories, Logan, UT) in the absence of antibiotics, except for the transfected HeLa cells which were maintained in 100 µg ml hygromycin B. In some experiments, cells were metabolically labeled with [S]methionine (300 µCi ml) as described(18) .

Membrane Vesicle Preparation

Plasma membrane vesicles were prepared as described (5, 22) with modifications(18) . Briefly, cells were homogenized in buffer containing 10 mM Tris-HCl, 250 mM sucrose, 3 mM KCl, 0.25 mM MgCl(2), pH 7.5, and protease inhibitors(18) . Cell pellets were frozen at -70 °C for at least 1 h, thawed, and then disrupted by N(2) cavitation (10 min equilibration at 175 p.s.i.). EDTA was added to 1 mM and after centrifugation at 500 times g for 15 min, the supernatant was layered over 35% (w/w) sucrose in 10 mM Tris-HCl, 1 mM EDTA (specific gravity, 1.15 g cm) and centrifuged at 100,000 times g for 2 h. The interface was collected and washed twice by centrifugation. The membrane pellet was resuspended in transport buffer (50 mM Tris-HCl, 250 mM sucrose, pH 7.5) and passed 20 times through a 27-gauge needle for vesicle formation. The resulting vesicles were enriched 4-8-fold in plasma membranes relative to the post-nuclear supernatant, as assessed by Na,K-ATPase, alkaline phosphatase, and 5`-nucleotidase activities ( (18) and references cited therein). Some contamination from endoplasmic reticulum was observed, as indicated by 2.3-fold enrichment of NADPH cytochrome c reductase.

The sidedness of the membrane vesicles was assessed by determining the activities of two plasma membrane-associated ectoenzymes (alkaline phosphatase and 5`-nucleotidase) in the presence or absence of 0.2% Nonidet P-40 (18, 23) and it was determined that 30-34% of T14 PM vesicles were inside-out. T14 vesicles were treated with concanavalin A (1:1 (w/w) ratio) overnight at 4 °C to agglutinate outside-out vesicles(24) . Following centrifugation to remove agglutinated material, the supernatant displayed a 2-fold increase in the rate of [^3H]LTC(4) uptake (see below), consistent with ATP-dependent transport being attributable to inside-out vesicles.

Vesicle Transport of LTC(4) and VCR

ATP-dependent transport of LTC(4) into membrane vesicles was measured by rapid filtration as described(16) , with modifications. Thawed membrane vesicles were diluted in transport buffer and passed 5 times through a 27-gauge needle. Standard transport assays were carried out at 23 °C in a 120-µl volume containing 10 µg of vesicle protein, 4 mM ATP, 10 mM MgCl(2), an ATP regenerating system consisting of 10 mM creatine phosphate and 100 µg ml creatine kinase, and [^3H]LTC(4) (50 nM; 100 nCi) in transport buffer. At the indicated times, 20-µl aliquots were removed and added to 1 ml of ice-cold transport buffer, which was then filtered through nitrocellulose filters (0.22 µm) on a Hoeffer filtration manifold under vacuum. Filters were immediately washed twice with 5 ml of cold transport buffer, solubilized, and radioactivity determined. [^3H]LTC(4) uptake was expressed relative to the protein concentration of the membrane vesicles(25) . All data were corrected for the amount of [^3H]LTC(4) that remained bound to the filter in the absence of vesicle protein, which was usually 5-10% of the total radioactivity.

ATP-dependent uptake of [^3H]VCR (200 nM; 70 nCi) was measured as described for [^3H]LTC(4) except that 100-120 µg of vesicle protein was used and the incubations were carried out at 37 °C. In some experiments, GSH (1-5 mM) was added to the transport buffer. Uptake of [^3H]VCR was stopped by rapid dilution in transport buffer and immediate filtration through glass fiber (Type A/E) filters (Gelman Sciences, Dorval, PQ), which had been presoaked overnight at 37 °C in 10% (w/v) bovine serum albumin(5) .

Photolabeling of Membrane Proteins with [^3H]LTC(4) and Immunoprecipitation of MRP

Membrane proteins were photolabeled with [^3H]LTC(4) essentially as described(16) . Briefly, vesicles prepared from different cell types (150 µg of membrane protein in 50 µl) were incubated with [^3H]LTC(4) (0.5 µCi, 78 nM) at room temperature for 10 min and frozen in liquid N(2). Samples were alternately irradiated for 30 s at 312 nm in a Stratalinker, followed by snap-freezing in liquid N(2), for a total of 10 min. A portion of the radiolabeled proteins was immunoprecipitated with a mixture of MRP-specific mAbs QCRL-1, QCRL-2, and QCRL-3(19) . Immunoprecipitates were solubilized in Laemmli's buffer and radiolabeled proteins (100 µg) were resolved by SDS-PAGE and gels were subjected to fluorography. To determine whether unlabeled LTC(4), LTB(4), mAb QCRL-3, or mouse IgG (isotype control) could inhibit [^3H]LTC(4) labeling, T14 membrane vesicles were coincubated with these reagents and [^3H]LTC(4) for 10 min at room temperature prior to irradiation and SDS-PAGE.


RESULTS

LTC(4) Uptake in Membrane Vesicles

The time course and ATP dependence of [^3H]LTC(4) accumulation by vesicles prepared from HeLa T14 cells is shown in Fig. 1A. Accumulation was measured at room temperature with an initial concentration of 50 nM LTC(4) in the presence of 4 mM ATP or AMP. No cations (Na, K, Ca) were present and the membrane potential was not experimentally manipulated. ATP-dependent uptake was rapid, linear up to 30 s and approached steady-state after 90 s (not shown). During the linear phase, the rate of ATP-dependent uptake was approximately 150 pmol mg min. Increasing the amount of vesicle protein resulted in rates of uptake which were difficult to quantify because of the short duration of linearity. Similarly, quantification was difficult if the experiments were carried out at 37 °C rather than room temperature because of high initial rates of transport and rapid depletion of extravesicular LTC(4). The ATP-dependent rate of LTC(4) uptake in T14 vesicles was at least 100-fold higher than in vesicles from control C6 cells (Fig. 1A). Furthermore, the low levels of uptake in T14 vesicles in the presence of AMP were similar to those observed for C6 membrane vesicles with or without ATP. The correlation between LTC(4) transport and levels of MRP expression was also examined by measuring rates of LTC(4) uptake in vesicles isolated from drug-sensitive H69, drug-resistant H69AR, and revertant H69PR cells. As shown in Fig. 1B, the rate of ATP-dependent [^3H]LTC(4) uptake in H69AR vesicles was approximately 2-fold faster than for T14 vesicles and was below the limits of detection in vesicles from H69 cells. Low levels of ATP-dependent [^3H]LTC(4) uptake could be detected in H69PR vesicles (approximately 1.5 pmol mg min at room temperature) (Fig. 1C) where the levels of MRP are 3-5-fold higher than in H69 cells(3, 19) . Vesicles from human 8226/Dox40 cells also exhibited levels of [^3H]LTC(4) transport comparable to those of H69PR-derived vesicles (approximately 2 pmol mg min) (Fig. 1D). These cells overexpress P-glycoprotein and contain low levels of MRP similar to those found in H69PR cells (data not shown).


Figure 1: Time course of [^3H]LTC(4) uptake by membrane vesicles from MRP and control transfected HeLa cells, parental and drug-selected H69 cells, and 8226/Dox40 cells. Membrane vesicles were incubated with 50 nM [^3H]LTC(4) in transport buffer (50 mM Tris-HCl, 250 mM sucrose, pH 7.5) for the times indicated. Closed symbols represent uptake in the presence of 4 mM AMP; open symbols represent uptake in the presence of 4 mM ATP. Vesicles were derived as described under ``Experimental Procedures'' from the following cell lines: Panel A, HeLa C6 (circle, bullet) and T14 (down triangle, ); Panel B, H69 (circle, bullet) and H69AR (up triangle, ); Panel C, H69PR (, ); Panel D, 8226/Dox40 (box, ). The dotted curve in Panel A (T14) and Panel B (H69AR) indicate ATP-dependent uptake, which was calculated by subtracting ATP-independent transport from transport in the presence of ATP. Data points are means of triplicate determinations (±S.E.) in a typical experiment.



Osmotic Sensitivity and Nucleotide and Cation Specificity of [^3H]LTC(4) Transport by T14 Membrane Vesicles

To confirm that LTC(4) accumulation reflected transport of substrate into the vesicle lumen, rather than surface or intramembrane binding, the effect of extravesicular osmolarity on [^3H]LTC(4) uptake was measured. As shown in Fig. 2A, the rate of [^3H]LTC(4) uptake in T14 vesicles was clearly osmotically-sensitive. To establish the nucleotide dependence of LTC(4) transport and to determine whether ATP hydrolysis was required, [^3H]LTC(4) uptake was measured in the presence of various nucleoside triphosphates and non-hydrolyzable ATP analogs. As shown in Fig. 2B, AMP-PNP, AMP-PCP, and ATPS (4 mM) were unable to support LTC(4) uptake, suggesting that ATP hydrolysis is necessary for transport. Of the four nucleoside triphosphates tested, LTC(4) uptake was most efficient in the presence of ATP (Fig. 2B).


Figure 2: Osmotic sensitivity and nucleotide and cation specificity of [^3H]LTC(4) transport by T14 membrane vesicles. Panel A, T14 membrane vesicles were preincubated for 10 min in transport buffer containing sucrose (0.25-1 M). Rates of [^3H]LTC(4) uptake were measured in the presence of 4 mM ATP () or 4 mM AMP () as described under ``Experimental Procedures.'' Panel B, rates of [^3H]LTC(4) uptake were measured in the presence of the indicated nucleotides (4 mM). No regenerating system was included in these experiments and the rate of transport in 4 mM ATP was not affected by its omission (solid bar). Results obtained with other nucleotides (hatched bars) are plotted as a % of values obtained with 4 mM ATP. The data shown are means of triplicate determinations (±S.E.) in a single experiment. Panel C, rates of [^3H]LTC(4) uptake were measured in the presence of 4 mM ATP and the indicated divalent cations (10 mM) (hatched bars). Results are plotted as a % of control LTC(4) uptake values obtained with 10 mM Mg at 30 s (solid bar). The results shown are means of triplicate determinations (±S.E.) in a single experiment and similar results were obtained in one additional experiment.



Since the activity of many ATPases is often maintained when other divalent cations are substituted for Mg, we investigated the level of ATP-dependent [^3H]LTC(4) transport in T14 vesicles in the presence of Mn, Ca, Co, Cd, Ba, and Zn (10 mM). The relative ability of these cations to support LTC(4) transport correlated well with their abilities to support ATP hydrolysis by known ATPases. Thus, when Mn, Ca, or Co were substituted for Mg, the [^3H]LTC(4) transport rates were measureable but reduced by 25, 50, and 65%, respectively, whereas Cd, Ba, and Zn did not support transport (Fig. 2C).

Inhibition of [^3H]LTC(4) Transport by ATPase Inhibitors

The inability of non-hydrolyzable ATP analogs to support MRP-mediated LTC(4) uptake and the effect of substituting various cations for Mg suggests that ATP hydrolysis, rather than just ATP-binding, is necessary for transport. Consequently, transport activity might be expected to be sensitive to inhibitors of certain classes of ATPases. For this reason, we examined the effects of the P-type ATPase inhibitor sodium vanadate, the Na,K-ATPase inhibitor ouabain, and the sulfhydryl reagent N-ethylmaleimide. [^3H]LTC(4) uptake was insensitive to ouabain and vanadate at concentrations up to 1 mM. Preincubation of membrane vesicles with 1 mMN-ethylmaleimide at 23 °C had no effect, but at 37 °C, [^3H]LTC(4) uptake was inhibited by 70%. This observation suggests that at least one cysteine residue may be important for transport, as has been shown for other transport ATPases (26) .

Kinetic Parameters of [^3H]LTC(4) Transport in T14 Vesicles

Rates of uptake were measured at several LTC(4) concentrations (12.5-1000 nM) to determine K(m) and V(max) for [^3H]LTC(4) transport in T14 membrane vesicles. As shown in Fig. 3A (inset), a Lineweaver-Burk double reciprocal plot yielded an apparent K(m) of 77 nM for LTC(4) and a V(max) of 291 pmol mg min. The average values (±S.E.) for K(m) and V(max) for six experiments were 105 ± 31 nM and 529 ± 176 pmol min mg, respectively. This K(m) value is in good agreement with that reported previously for vesicles from human MRP-transfected HeLa T5 cells (97 nM)(10) , and for [^3H]LTC(4) transport in murine mastocytoma membrane vesicles (70 nM) (16) . The V(max) obtained with T14 vesicles is approximately 5-fold higher than the value previously reported for vesicles prepared from HeLa T5 cells transfected with a different MRP expression vector (100 pmol min mg)(10) . The levels of MRP in T14 cells are 2-fold higher than in T5 cells (15) which may explain the differences in V(max). However, it is also possible that differences in procedures used to prepare vesicles may contribute to the higher V(max) values obtained with T14 vesicles.


Figure 3: Effect of substrate and ATP concentration on [^3H]LTC(4) uptake. Panel A, [^3H]LTC(4) uptake by T14 membrane vesicles was measured at various LTC(4) concentrations (12.5-1000 nM) for 30 s at 23 °C. Data are plotted as V(o)versus [S] to confirm that the appropriate concentration range was selected to observe both zero-order and first-order rate kinetics. Kinetic parameters were determined from regression analysis of the Lineweaver-Burk transformation of the data (inset). Panel B, ATP-dependent uptake of [^3H]LTC(4) was measured at various concentrations of ATP (2 µM to 4 mM) in the presence of 50 nM [^3H]LTC(4). Uptake at ATP concentrations up to 250 µM are plotted. Kinetic parameters were determined from regression analysis of the Lineweaver-Burk data transformation (inset).



The apparent K(m) for ATP (70 µM) was determined by measuring initial rates of [^3H]LTC(4) uptake at 30 s in the presence of different concentrations of the nucleotide (2-4000 µM) (Fig. 3B, inset).

Photolabeling of Membrane Proteins with [^3H]LTC(4) and Inhibition of Transport with MRP-specific MAb QCRL-3

Previous studies have shown that LTC(4) will bind to a 190-kDa protein enriched in membranes from MRP transfected cells(10) . To demonstrate conclusively that the labeled 190-kDa protein was MRP, T14 vesicles were incubated with [^3H]LTC(4), uv irradiated to cross-link bound LTC(4), and solubilized membranes were immunoprecipitated with MRP-specific mAbs(19) . After SDS-PAGE of the immunoprecipitate, a [^3H]LTC(4)-labeled 190-kDa protein (Fig. 4A, lane 3) was detected which co-migrated with [S]methionine-labeled MRP immunoprecipitated with the same mAbs (Fig. 4A, lane 1). In addition, the MRP-specific mAb QCRL-3, which recognizes a conformation-dependent epitope, inhibited [^3H]LTC(4) uptake with an IC of 5 µg ml (50 ng of mAb times µg protein) (Fig. 4B). The MRP-specific mAb QCRL-1, which recognizes a linear MRP epitope, had no effect on LTC(4) transport (not shown) nor did isotype control immunoglobulins up to 30 µg ml .


Figure 4: Photolabeling of vesicle proteins and inhibition of [^3H]LTC(4) uptake and photolabeling by MRP-specific mAb QCRL-3. Panel A, T14 membrane vesicles were photolabeled with [^3H]LTC(4) and membrane protein (50 or 120 µg) was analyzed by SDS-PAGE and fluorography. Alternatively, membranes (100 µg of protein) were photolabeled and immunoprecipitated with a mixture of three MRP-specific mAbs ([^3H]LTC(4), middle lane)(19) . For comparison, immunoprecipitations were also performed on membranes prepared from cells labeled in culture with [S]methionine (S-Ippt, far left lane)(18) . Panel B, [^3H]LTC(4) uptake was measured in the presence of MRP-specific mAb QCRL-3. Each point represents the mean of triplicate determinations (±S.E.) in a single experiment. In the experiment shown, the rate of uptake in control incubations was 174 pmol mg min. Panel C, membrane vesicle protein (approx150 µg) from 8226/Dox40, H69AR, C6, or T14 cells was incubated with [^3H]LTC(4) (0.5 µCi; 78 nM) in transport buffer, irradiated at 312 nm, and analyzed by SDS-PAGE and fluorography (see ``Experimental Procedures''). T14 membrane vesicles were also incubated with [^3H]LTC(4) in the presence of excess unlabeled LTC(4), LTB(4), MRP-specific mAb QCRL-3 (10 µg ml), and murine IgG (70 µg ml), prior to irradiation and SDS-PAGE and fluorography. The autoradiograms shown represent a 14-day exposure.



To examine the specificity of the interaction between LTC(4) and MRP, the ability of unlabeled LTC(4) or the unconjugated leukotriene, LTB(4), to compete for [^3H]LTC(4) labeling of membrane proteins was determined (Fig. 4C). In the absence of competitor, photolabeling of MRP was readily detectable in H69AR (Fig. 4C, lane 2) and T14 (Fig. 4C, lane 4), but not in C6 membranes (Fig. 4C, lane 3), as expected. The relative degree of labeling was consistent with the relative level of MRP in these cells. Photolabeling was inhibited by excess unlabeled LTC(4) (Fig. 4C, lane 5), but not LTB(4) (Fig. 4C, lane 6). Labeling was also inhibited by mAb QCRL-3 (Fig. 4C, lane 7) at a concentration which abolishes [^3H]LTC(4) transport (100 ng times µg protein). MAb QCRL-1 did not inhibit photolabeling (not shown), consistent with its inability to inhibit LTC(4) transport. Finally, to exclude the possibility that LTC(4) labeling of MRP was an artifact resulting from nonspecific labeling of an abundant integral membrane protein, labeling experiments were carried out with 8226/Dox40 vesicles known to contain high levels of P-glycoprotein. As shown in Fig. 4C (lane 1), no labeling with [^3H]LTC(4) was observed.

Inhibition of [^3H]LTC(4) Uptake by Alkylated GSH Derivatives

It has been reported previously that the transporter(s) responsible for GSH S-conjugate in sarcolemmal (27) and hepatocanalicular (28, 29) membranes is inhibited by alkylated GSH derivatives. Consequently, we investigated whether these compounds had a similar effect on MRP-mediated [^3H]LTC(4) transport in T14 vesicles. Inhibition of uptake increased with the length of the alkyl chain and hence with the hydrophobicity of the GSH derivative (Fig. 5A). For example, S-octyl- and S-decyl-GSH inhibited LTC(4) uptake by more than 60% at concentrations as low as 100 nM. GSH alone did not inhibit LTC(4) transport even at 5 mM. In contrast, GSSG inhibited transport with an IC of 100 µM (data not shown)(12) . Inhibition of LTC(4) transport by S-decyl-GSH was further characterized by determining the kinetic parameters of inhibition. These experiments showed that S-decyl-GSH is a competitive inhibitor with an apparent K(i) of 116 nM (Fig. 5B).


Figure 5: Effect of alkylated GSH derivatives on [^3H]LTC(4) uptake in MRP-enriched membrane vesicles. Panel A, [^3H]LTC(4) uptake into T14 membrane vesicles was measured in the presence of the indicated concentrations of GSH derivatives. Results are plotted as a % of ATP-dependent [^3H]LTC(4) uptake in the absence of GSH derivative and each bar represent the mean (± S.E.) of triplicate determinations in a typical experiment. The control uptake rate in this experiment was 190 pmol mg min. Panel B, uptake of [^3H]LTC(4) was measured in the presence of various concentrations of S-decyl-GSH (control, bullet; 50 nM, circle; 100 nM, ; 250 nM, up triangle). Double-reciprocal plots were generated and an apparent K of 116 nM was calculated from the apparent K and V(max) in the presence of S-decyl-GSH.



Inhibition of [^3H]LTC(4) Transport in Membrane Vesicles by Chemotherapeutic Agents and LTB(4)

Several chemotherapeutic agents and the non-cysteinyl leukotriene LTB(4) were tested for their ability to inhibit [^3H]LTC(4) transport and the results are shown in Fig. 6. Daunorubicin, doxorubicin, colchicine, and VP-16 at 100 µM and taxol at 40 µM inhibited uptake by only 35-55% (Fig. 6A). A modest enhancement of [^3H]LTC(4) transport inhibition was observed when the vesicles were coincubated with GSH (1 mM), and colchicine, taxol, or VP-16, but not daunorubicin or doxorubicin (Fig. 6A). The small effect seen with colchicine, taxol, and VP-16 may be attributable to the weak inhibition (<15%) of transport exhibited by GSH itself (not shown). In contrast, although VCR and vinblastine alone were also poor inhibitors of [^3H]LTC(4) transport (30-50% inhibition at 100 µM), this inhibition was markedly enhanced by coincubation with GSH (1 mM). In the presence of GSH, 50-60 and 90-100% inhibition by vinblastine and VCR was observed at drug concentrations of 10 and 100 µM, respectively (Fig. 6B). 2-Mercaptoethanol or dithiothreitol (1 mM) had no effect on the inhibitory potency of vinblastine or VCR (data not shown), indicating that the enhancing effect of GSH was not simply due to its reducing capacity. As expected, LTB(4) was a poor inhibitor of LTC(4) transport, showing little effect at 10 µM, and requiring 100 µM (2000-fold molar excess compared to LTC(4)) to inhibit uptake by 80% (Fig. 6B). The inhibition by this non-cysteinyl leukotriene was not augmented by GSH.


Figure 6: Effect of chemotherapeutic agents and LTB(4) on [^3H]LTC(4) uptake by T14 vesicles. The ability of drugs and LTB(4) to inhibit [^3H]LTC(4) uptake was measured in the absence or presence of GSH (1 mM) for 30 s at 23 °C. Results were calculated as a % of control values obtained in the absence of both drug and GSH. The bars represent the means (±S.E.) of triplicate determinations in a single experiment and similar results were obtained in at least one additional experiment. Panel A, the control uptake rate in this experiment was 185 pmol mg min. DOX, doxorubicin; DNR, daunorubicin; CLC, colchicine; TXL, taxol. Panel B, the control uptake rate in this experiment was 155 pmol mg min. VBL, vinblastine.



[^3H]Vincristine Transport in Membrane Vesicles

The ability of GSH to enhance inhibition of LTC(4) transport by vinblastine and VCR suggested that GSH may also play a role in the transport of these Vinca alkaloids. To investigate this possibility directly, we examined the effect of GSH on [^3H]VCR uptake. These experiments were performed as described for LTC(4) uptake, except that they were carried out at 37 °C, the concentration of substrate (VCR) was 200 nM, 10-12-fold more vesicle protein was used, and washing conditions were modified to minimize nonspecific binding of VCR to the filters. No ATP-dependent uptake of [^3H]VCR uptake could be detected in either C6 or T14 vesicles and steady-state levels of vesicle-associated VCR were very low (approximately 3 and 6 pmol mg for C6 and T14 vesicles, respectively, at 20 min) (Fig. 7A). In contrast, ATP-dependent [^3H]VCR uptake was demonstrable in T14 but not C6 vesicles when GSH was added and this effect was concentration dependent (Fig. 7B). Thus, in the presence of 1, 3, and 5 mM GSH, steady state levels of ATP-dependent VCR uptake in T14 vesicles were increased to approximately 15, 22, and 31 pmol mg, respectively, at 20 min. 2-Mercaptoethanol, dithiothreitol, or L-cysteine (up to 5 mM) did not increase VCR uptake, indicating that it was not the reducing capacity of GSH that was responsible for the increase in VCR uptake (Fig. 7B). [^3H]VCR uptake by T14 vesicles was osmotically-sensitive (not shown) and was inhibitable by 500 µM GSSG (23 ± 5% control), and 200 µMN-ethylmaleimide (45 ± 5% control), but not by 200 µM vanadate (85 ± 8% control), consistent with the effect of these reagents on LTC(4) transport.


Figure 7: Vincristine uptake in membrane vesicles from MRP-transfected HeLa cells. Panel A, membrane vesicles from HeLa C6 (circle, bullet) and T14 (down triangle, ) cells were incubated with 200 nM [^3H]VCR in transport buffer at 37 °C for the times indicated. Closed symbols represent uptake in the presence of 4 mM AMP; open symbols represent uptake in the presence of 4 mM ATP. Panel B, T14 vesicles were incubated for 10 min in 200 nM [^3H]VCR in buffer containing 4 mM AMP, ATP, or ATP and an ATP-regenerating system (ATP/RS) as described under ``Experimental Procedures.'' Transport was measured in the absence and presence of the indicated concentrations of GSH and 2-mercaptoethanol (2-ME). Bars represent the means (±S.E.) of triplicate determinations in a typical experiment and similar results were found in three additional experiments.




DISCUSSION

Both P-glycoprotein and MRP are capable of causing resistance to a similar spectrum of drugs when overexpressed in mammalian cells(1, 8) . Transfection of MRP or P-glycoprotein into drug-sensitive cells has been shown to result in reduced drug accumulation(8, 30) . In the case of P-glycoprotein, there is considerable experimental evidence the protein causes resistance by binding and transporting drugs out of the cell or plasma membrane in an ATP-dependent fashion(2, 9, 31) . The mechanism by which MRP mediates reduced drug accumulation in resistant cells is less well understood and in contrast to P-glycoprotein, there is no evidence that unmodified chemotherapeutic agents bind directly to, or are transported by, the protein(7, 8) .

In the present study, we further characterized the transport properties of MRP using membrane vesicles derived from both drug-selected MRP-overexpressing cells and a population of transfected HeLa cells(8, 18) . We found high-affinity rapid transport of LTC(4) in T14 vesicles that was osmotically sensitive, required hydrolyzable nucleotides, and was supported only by those divalent cations that support the activity of other membrane ATPases, thus providing evidence that ATP hydrolysis as well as binding is required for transport. Transport rates were somewhat lower in T14 vesicles than in vesicles from the drug-selected H69AR cells, in keeping with the relative levels of MRP expression in these two cell types(8) . The low but detectable transport in revertant H69PR cells was also consistent with the low levels of MRP in these cells(3, 19) . The absence of significant LTC(4) transport in vesicles from P-glycoprotein-overexpressing 8226/Dox40 cells confirmed the MRP-specificity of this transport process. These observations confirm and extend previous studies demonstrating that MRP-enriched vesicles are capable of LTC(4) transport(10, 11, 12) . Binding of LTC(4) to MRP was shown by immunoprecipitation of a 190-kDa [^3H]LTC(4) photoaffinity labeled T14 membrane protein with MRP-specific mAbs. MAb QCRL-3 which detects a conformation-dependent epitope of MRP, also strongly inhibited LTC(4) transport and prevented [^3H]LTC(4) labeling of MRP. Taken together, these observations provide strong evidence that LTC(4) binds directly to MRP before being transported and further suggest that LTC(4) binds to MRP at a site within or near the epitope detected by mAb QCRL-3.

LTC(4) is the highest affinity substrate identified to date for MRP and while some modifications of the glutathione or arachidonate moieties of the molecule are tolerated, levels of transport are usually diminished by these changes(10) . Our present studies demonstrate that LTC(4) transport by MRP is effectively inhibited by alkylated GSH derivatives. The inhibitory potency of alkylated GSH derivatives with respect to LTC(4) transport in hepatocanalicular (28, 29) and sarcolemmal (27) membranes has been shown to increase proportionately with the length of the alkyl chain. We also found this to be the case in vesicles from MRP transfectants. Indeed, LTC(4) transport by MRP was significantly more sensitive to inhibition by these compounds than reported for the transporters in rat muscle and liver(27, 29) . Inhibition of MRP-mediated LTC(4) transport by the most potent GSH derivative, S-decyl-GSH, was competitive, suggesting that it binds to a site in MRP that is similar or possibly overlapping the site to which LTC(4) binds. The K(i) (116 nM) for S-decyl-GSH was similar to the apparent K(m) (105 nM) for LTC(4) transport in T14 membrane vesicles, indicating that this GSH derivative is potentially a high affinity substrate for MRP.

In contrast to cysteinyl leukotrienes and alkylated GSH derivatives, we and others have found that chemotherapeutic drugs are poor inhibitors of LTC(4) transport, exerting significant inhibition only at concentrations 200-2000-fold greater than the K(m) of LTC(4)(12, 32) . However, we observed that inhibition of LTC(4) transport by certain drugs, most notably the Vinca alkaloids VCR and vinblastine, could be significantly enhanced by incubation with physiological concentrations of GSH. Why this enhancement is more pronounced with these two drugs than with others is presently unclear. It does not appear to be simply related to the relative degree of MRP-mediated resistance to a particular agent since T14 cells are considerably more resistant to VCR, doxorubicin, and daunorubicin than they are to vinblastine(8) . Nevertheless, the ability of both Vinca alkaloids to inhibit LTC(4) transport in T14 membrane vesicles is similarly and markedly enhanced by GSH while inhibition by doxorubicin and daunorubicin are unaffected. A similar potentiating effect of GSH is observed for inhibition of 17beta-estradiol 17-(beta-D-glucuronide) transport by MRP (44) . This effect appears specific for GSH since other thiols (2-mercaptoethanol, L-cysteine, and dithiothreitol) or other organic anions such as glucuronic acid could not substitute for GSH.

We also found that the presence of GSH resulted in demonstrable ATP-dependent [^3H]VCR transport by MRP-enriched vesicles. ATP-dependent uptake of [^3H]VCR was approximately 31 pmol mg at steady state in the presence of 200 nM VCR and 5 mM GSH. This is substantially lower than steady state levels of LTC(4) uptake, GSSG uptake(33) , and 17beta-estradiol 17-(beta-D-glucuronide) uptake (44) in MRP-enriched vesicles but is comparable to that reported for vinblastine uptake in vesicles from certain cell lines overexpressing P-glycoprotein(6, 34) .

The mechanism by which GSH enables ATP-dependent VCR transport by MRP, and possibly other chemotherapeutic agents as well, is unclear. GSH has also been reported to potentiate binding of the hydrophobic ligand MK 801 to the integral membrane NMDA receptor (35) but whether the mechanism involved is similar to that which potentiates VCR transport is unknown. It is possible that MRP contains a bipartite binding site for hydrophobic and anionic moieties that would allow binding of non-covalent drug-GSH complexes, or the sequential binding of GSH and drug. Occupation of both elements of the site may be necessary before transport can occur. At present, there is no convincing evidence that GSH is actively co-transported with drug. GSH by itself is not a substrate for transport by MRP(33) , and neither does it inhibit LTC(4) transport, even at 5 mM, the highest intracellular concentration likely to be encountered in vivo. In contrast, GSSG caused 50% inhibition of LTC(4) transport at approximately 100 µM. Finally, it has been reported that transport of daunorubicin by MRP does not increase GSH release by intact cells(36, 37) . Thus it appears unlikely that MRP transports drugs in association with reduced GSH. Alternatively, interaction of GSH with MRP may cause a conformational change (37) or an alteration in the exposure of nonpolar residues, that may favor binding of some hydrophobic compounds prior to transport. Further studies are required to elucidate precisely how GSH enhances VCR transport.

In addition to the cysteinyl leukotrienes and vincristine in the presence of GSH, MRP can transport 17beta-estradiol 17-(beta-D-glucuronide) and possibly certain other cholestatic steroid glucuronides(44) . We have determined that LTC(4) can inhibit 17beta-estradiol 17-(beta-D-glucuronide) transport and vice versa. Consequently, the presence of a cysteinyl residue is not absolutely required for a compound to be a substrate for MRP-mediated transport. A number of organic anions and cyclic peptides which are neither GSH nor glucuronide conjugates such as MK 571 (K(i) 0.6 µM) (16, 38) and cyclosporin A (K(i) 5 µM) (10) can behave as competitive inhibitors of LTC(4) transport in membrane vesicles from drug-selected cells known to overexpress MRP. Since cyclosporin A is not an effective chemosensitizer in MRP-overexpressing cells(30, 39, 40) , the ability of a compound to inhibit LTC(4) transport is clearly not always indicative of its capacity to reverse MRP-associated resistance nor its ability to act as a substrate.

We and others have clearly shown that MRP-overexpressing cells are not resistant to cisplatin(8, 20, 30, 41, 42) . The presence of ATP-dependent transport of a glutathione-platinum complex in a platinum-resistant cell line has been demonstrated and it was suggested that the transporter or ``GS-X pump'' in these cells may be MRP(43) . Although this transport activity is pharmacologically similar to MRP in some respects, in that it is inhibitable by LTC(4), GSSG, and S-dinitrophenylglutathione, the overexpression of MRP mRNA and protein in these cells has not been shown. Furthermore, we found that cisplatin did not inhibit LTC(4) transport in T14 vesicles either by itself or in combination with GSH (results not shown). Finally, Muller and co-workers (12) were unable to demonstrate LTC(4) transport in a platinum-resistant lung cancer cell line which exhibits reduced drug accumulation. Thus current evidence suggests that MRP is not involved in conferring resistance to platinum-containing drugs although it remains possible that a transporter related to MRP may be responsible, at least in some platinum-resistant cell lines.

To date, there is little known about the mechanism of ATP-dependent MRP-mediated transport of cysteinyl leukotrienes, steroid glucuronides, or drugs in association with GSH. However, it is possible that substrate binding by MRP (in the presence of GSH in the case of chemotherapeutic drugs) facilitates the binding and subsequent hydrolysis of ATP, which in turn induces a conformational change in MRP that allows for the release of the transported molecule(s) into the extracellular space. Experiments aimed at determining whether the ATPase activity of MRP is stimulated by LTC(4), 17beta-estradiol 17-(beta-D-glucuronide), or chemotherapeutic agents in the absence or presence of GSH are underway. Mapping of the mAb QCRL-3 epitope is also in progress and together with proteolytic mapping studies of [^3H]LTC(4)-labeled MRP, should allow the LTC(4) binding site on the MRP molecule to be identified.


FOOTNOTES

*
This work was supported in part by a grant from the Medical Research Council of Canada (MRCC) (to S. P. C. C. and R. G. D.).

§
Supported by an MRCC studentship.

Stauffer Research Professor of Queen's University.

**
Career Scientist of the Ontario Cancer Foundation. To whom correspondence and reprint requests should be addressed: Cancer Research Laboratories, Rm. 328, Botterell Hall, Queen's University, Kingston, Ontario, Canada, K7L 3N6. Tel.: 613-545-6507; Fax: 613-545-6830.

(^1)
The abbreviations used are: MRP, multidrug resistance protein; AMP-PCP, beta,-methyleneadenosine 5`-triphosphate; AMP-PNP, adenosine 5`-[beta,-imido]triphosphate; ATPS, adenosine 5`-O-(3-thiotriphosphate); LTC(4), leukotriene C(4); LTB(4), leukotriene B(4); mAb, monoclonal antibody; VCR, vincristine; PAGE, polyacrylamide gel electrophoresis.


ACKNOWLEDGEMENTS

We thank D. R. Hipfner for mAbs and C. E. Grant for transfected HeLa cells. We also thank Drs. D. Keppler and I. Leier for helpful discussions. The technical assistance of K. Sparks and K. Fraser is gratefully acknowledged.


REFERENCES

  1. Loe, D. W., Deeley, R. G., and Cole, S. P. C. (1996) Eur. J. Cancer , in press
  2. Gottesman, M. M., and Pastan, I. (1993) Annu. Rev. Biochem. 62, 385-427 [CrossRef][Medline] [Order article via Infotrieve]
  3. Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., and Deeley, R. G. (1992) Science 258, 1650-1654 [Medline] [Order article via Infotrieve]
  4. Sharom, F. J. (1995) J. Bioenerg. Biomembr. 27, 15-22 [Medline] [Order article via Infotrieve]
  5. Doige, C. A., and Sharom, F. J. (1992) Biochim. Biophys. Acta 1109, 161-171 [Medline] [Order article via Infotrieve]
  6. Schlemmer, S. R., and Sirotnak, F. M. (1994) J. Biol. Chem. 269, 31059-31066 [Abstract/Free Full Text]
  7. McGrath, T., Latoud, C., Arnold, S. T., Safa, A. R., Felsted, R. L., and Center, M. S. (1989) Biochem. Pharmacol. 38, 3611-3619 [Medline] [Order article via Infotrieve]
  8. Cole, S. P. C., Sparks, K. E., Fraser, K., Loe, D. W., Grant, C. E., Wilson, G. M., and Deeley, R. G. (1994) Cancer Res. 54, 5902-5910 [Abstract]
  9. Safa, A. R. (1992) Cancer Invest. 10, 295-305
  10. Leier, I., Jedlitschky, G., Buchholz, U., Cole, S. P. C., Deeley, R. G., and Keppler, D. (1994) J. Biol. Chem. 269, 27807-27810 [Abstract/Free Full Text]
  11. Jedlitschky, G., Leier, I., Buchholz, U., Center, M., and Keppler, D. (1994) Cancer Res. 54, 4833-4836 [Abstract]
  12. Muller, M., Meijer, C., Zaman, G. J. R., Borst, P., Scheper, R. J., Mulder, N. H., DeVries, E. G. E., and Jansen, P. L. M. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 13033-13037 [Abstract/Free Full Text]
  13. Keppler, D. (1992) Rev. Physiol. Biochem. Pharmacol. 121, 1-30 [Medline] [Order article via Infotrieve]
  14. Nicholson, D. W., Ali, A., Vaillancourt, J. P., Calaycay, J. R., Mumford, R. A., Zamboni, R. J., and Ford-Hutchinson, A. W. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 2015-2019 [Abstract]
  15. Schaub, T., Ishikawa, T., and Keppler, D. (1991) FEBS Lett. 279, 83-86 [CrossRef][Medline] [Order article via Infotrieve]
  16. Leier, I., Jedlitschky, G., Buchholz, U., and Keppler, D. (1994) Eur. J. Biochem. 220, 599-606 [Abstract]
  17. Tew, K. D. (1994) Cancer Res. 54, 4313-4320 [Abstract]
  18. Almquist, K. C., Loe, D. W., Hipfner, D. R., Mackie, J. E., Cole, S. P. C., and Deeley, R. G. (1995) Cancer Res. 55, 102-110 [Abstract]
  19. Hipfner, D. R., Gauldie, S. D., Deeley, R. G., and Cole, S. P. C. (1994) Cancer Res. 54, 5788-5792 [Abstract]
  20. Mirski, S. E. L., Gerlach, J. H., and Cole, S. P. C. (1987) Cancer Res. 47, 2594-2598 [Abstract]
  21. Dalton, W. S., Durie, B. G. M., Alberts, D. S., Gerlach, J. H., and Cress, A. E. (1986) Cancer Res. 46, 5125-5130 [Abstract]
  22. Cornwell, M. M., Gottesman, M. M., and Pastan, I. H. (1986) J. Biol. Chem. 261, 7921-7928 [Abstract/Free Full Text]
  23. Ellman, G. L., Courtney, K. D., Andres, V., Jr., and Featherstone, R. M. (1961) Biochem. Pharmacol. 7, 88-95 [CrossRef][Medline] [Order article via Infotrieve]
  24. Ruetz, S., Raymond, M., and Gros, P. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 11588-11592 [Abstract]
  25. Bradford, M. M. (1976) Anal. Biochem. 72, 248-254 [CrossRef][Medline] [Order article via Infotrieve]
  26. Blumrich, M., and Petzinger, E. (1990) Biochim. Biophys. Acta 1029, 1-12 [Medline] [Order article via Infotrieve]
  27. Ishikawa, T. (1989) J. Biol. Chem. 264, 17343-17348 [Abstract/Free Full Text]
  28. Ishikawa, T., Kobayashi, K., Sogame, Y., and Hayashi, K. (1989) FEBS Lett. 259, 95-98 [CrossRef][Medline] [Order article via Infotrieve]
  29. Ballatori, N., and Truong, A. T. (1995) J. Biol. Chem. 270, 3594-3601 [Abstract/Free Full Text]
  30. Zaman, G. J. R., Flens, M. J., van Leusden, M. R., De Haas, M., Mulder, H. S., Lankelma, J., Pinedo, H. M., Scheper, R. J., Baas, F., Broxterman, H. J., and Borst, P. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 8822-8826 [Abstract]
  31. Georges, E., Sharom, F. J., and Ling, V. (1990) Adv. Pharmacol. 21, 185-220 [Medline] [Order article via Infotrieve]
  32. Ishikawa, T., Muller, M., Klunemann, C., Schaub, T., and Keppler, D. (1990) J. Biol. Chem. 265, 19279-19286 [Abstract/Free Full Text]
  33. Leier, I., Jedlitschky, G., Buchholz, U., Center, M., Cole, S. P. C., Deeley, R. G., and Keppler, D. (1996) Biochem. J. 314, 433-437 [Medline] [Order article via Infotrieve]
  34. Schlemmer, S. R., and Sirotnak, F. M. (1995) Anal. Biochem. 228, 226-231 [CrossRef][Medline] [Order article via Infotrieve]
  35. Ogita, K., Enomoto, R., Nakahara, F., Ishitsubo, N., and Yoneda, Y. (1995) J. Neurochem. 64, 1088-1096 [Medline] [Order article via Infotrieve]
  36. Zaman, G. J. R., Lankelma, J., Van Tellingen, O., Beijnen, J., Dekker, H., Paulusma, C., Oude Elferink, R. P. J., Baas, F., and Borst, P. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 7690-7694 [Abstract]
  37. Versantvoort, C. H. M., Broxterman, H. J., Bagrij, T., Scheper, R. J., and Twentyman, P. R. (1995) Br. J. Cancer 72, 82-89 [Medline] [Order article via Infotrieve]
  38. Lam, B. K., Xu, K., Atkins, M. B., and Austen, K. F. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 11598-11602 [Abstract]
  39. Cole, S. P. C. (1992) Can. J. Physiol. Pharmacol. 70, 313-329 [Medline] [Order article via Infotrieve]
  40. Barrand, M. A., Rhodes, T., Center, M. S., and Twentyman, P. R. (1993) Eur. J. Cancer 29A, 408-415
  41. Twentyman, P. R., Fox, N. E., Wright, K. A., and Bleehen, N. M. (1986) Br. J. Cancer 53, 529-537 [Medline] [Order article via Infotrieve]
  42. Grant, C. E., Valdimarsson, G., Hipfner, D. R., Almquist, K. C., Cole, S. P. C., and Deeley, R. G. (1994) Cancer Res. 54, 357-361 [Abstract]
  43. Ishikawa, T., Wright, C. D., and Ishizuka, H. (1994) J. Biol. Chem. 269, 29085-29093 [Abstract/Free Full Text]
  44. Loe, D. W., Almquist, K. C., Cole, S. P. C., and Deeley, R. G. (1996) J. Biol. Chem. 271, 9683-9689 [Abstract/Free Full Text]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.